Barclays Maintains an 'Overweight' on Oracle (ORCL); Expecting In-line Q4 as Risks Are Balanced
Tweet
Share
E-mailGet Alerts ORCL Hot Sheet
Price: $146.65 --0%
Rating Summary:
48 Buy, 21 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 20
Rating Summary:
48 Buy, 21 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 20
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Oracle (NASDAQ: ORCL) price target of $37.00.
Analyst, Raimo Lenschow, said, "In our view, numbers are likely to be in line. On the one hand, Q4 consensus is well below normal seasonality, while Q1 FY13 consensus appears to be seasonally normal. However, there are good reasons to be cautious. 1) Q4 and Q1 comparables are relatively tough; 2) macroeconomic data have been uninspiring; 3) recent USD strength presents a FX headwind; and 4) sentiment at the end of May was particularly negative."
Barclays slightly lowers FY12 EPS estimate from $2.42 to $2.40 and FY13 from $2.69 to $2.67.
For an analyst ratings summary and ratings history on Oracle click here. For more ratings news on Oracle click here.
Shares of Oracle closed at $27.16 yesterday.
Analyst, Raimo Lenschow, said, "In our view, numbers are likely to be in line. On the one hand, Q4 consensus is well below normal seasonality, while Q1 FY13 consensus appears to be seasonally normal. However, there are good reasons to be cautious. 1) Q4 and Q1 comparables are relatively tough; 2) macroeconomic data have been uninspiring; 3) recent USD strength presents a FX headwind; and 4) sentiment at the end of May was particularly negative."
Barclays slightly lowers FY12 EPS estimate from $2.42 to $2.40 and FY13 from $2.69 to $2.67.
For an analyst ratings summary and ratings history on Oracle click here. For more ratings news on Oracle click here.
Shares of Oracle closed at $27.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
- BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
- William Blair Starts Enliven Therapeutics (ELVN) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
